The Epilepsy Foundation Research Department’s purpose is to develop an epilepsy research ecosystem that covers the entire spectrum of discovery – from the idea to market. We foster the development of new scientists and support research that leads to better treatments and care. We strive for excellence, innovation, and radical thinking to find cures.
“Our research has no boundaries. We go where the science is. Over the past ten years, we have funded research on 6 continents.”
In 2017, the Epilepsy Therapy Project began supporting the first genetic therapy (Ataluren) for epilepsy.
In 2013, the Epilepsy Therapy Project supported the first Epidiolex® (CBD) trial by GW Pharmaceuticals (Greenwich Biosciences) for Dravet and Lennox-Gastaut.
In 2011, the SharkTank award went to SAMiTM by HiPass Designs for developing a sleep activity monitor to detect abnormal movements in the night.
You can help in the fight to End Epilepsy. Take an active role in research.Find a Clinical Trial